Testing Lunsekimig Injections Against Placebo in Adults With COPD
Tests the injected drug lunsekimig against placebo in adults with COPD.
Plain-language title generated from the registry record
Registry title: Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
Key facts
- Where
- Adairsville, Allen Park, Austin, Baltimore, Beckley, Birmingham, Boulder, Brandon, Brighton, Buffalo, Champaign, Chattanooga, Columbia, Dallas, DeLand, Denison, Detroit, El Paso, Farmington Hills, Greenacres City, Greenville, Hamilton, Hammond, Hannibal, Hendersonville, Hialeah, Houston, Jacksonville, Lakewood, Las Vegas, Lehigh Acres, Long Beach, Los Angeles, Loxahatchee Groves, Media, Miami, Missouri City, Mobile, New Bedford, New Windsor, Newark, Normal, Northridge, Orlando, Pensacola, Peoria, Plantation, Portland, San Diego, Sarasota, Shreveport, St Louis, St. Petersburg, Statesville, Sugar Land, Tampa, Toledo, Tucson, Tulsa, Washington D.C., Winston-Salem, and Wylie, United StatesSee the 75 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 80 years old?
Source: NCT07190222, who can take part
Where in United States
- AdairsvilleAdairsville, United StatesTaking people
- Vitalis Clinical Research Center- Site Number : 8400040Allen Park, United StatesTaking people
- AustinAustin, United StatesTaking people
- Johns Hopkins Bayview Medical Center- Site Number : 8400076Baltimore, United StatesTaking people
- Rheumatology & Pulmonary Clinic- Site Number : 8400012Beckley, United StatesTaking people
- University of Alabama at Birmingham- Site Number : 8400003Birmingham, United StatesTaking people
- Alpine Clinical Research Center - Boulder - 47th Street- Site Number : 8400005Boulder, United StatesTaking people
- BrandonBrandon, United StatesTaking people
- BrightonBrighton, United StatesTaking people
- Trinity Medical, WNY- Site Number : 8400157Buffalo, United StatesTaking people
- Christie Clinic in Champaign on University- Site Number : 8400023Champaign, United StatesTaking people
- Chattanooga Research and Medicine- Site Number : 8400026Chattanooga, United StatesTaking people
- ColumbiaColumbia, United StatesTaking people
- DallasDallas, United StatesTaking people
- Hillcrest Medical Research- Site Number : 8400082DeLand, United StatesTaking people
- Premier Pulmonary Critical Care and Sleep- Site Number : 8400111Denison, United StatesTaking people
- Henry Ford Hospital- Site Number : 8400058Detroit, United StatesTaking people
- El Paso Pulmonary Association- Site Number : 8400033El Paso, United StatesTaking people
- Pulmonary Research Institute of Southeast Michigan - Farmington Hills- Site Number : 8400161Farmington Hills, United StatesTaking people
- Finlay Medical Research - Greenacres- Site Number : 8400107Greenacres City, United StatesTaking people
- East Carolina University- Site Number : 8400102Greenville, United StatesTaking people
- Bioluminux Clinical Research - Hamilton, New Jersey- Site Number : 8400037Hamilton, United StatesTaking people
- Asha Clinical Research - Munster- Site Number : 8400115Hammond, United StatesTaking people
- Hannibal Regional Healthcare System- Site Number : 8400035Hannibal, United StatesTaking people
- Premier Research Center, Llc- Site Number : 8400146Hendersonville, United StatesTaking people
- Direct Helpers Research Center- Site Number : 8400057Hialeah, United StatesTaking people
- HoustonHouston, United StatesTaking people
- Aavon Clinical Trials, Llc- Site Number : 8400166Houston, United StatesTaking people
- Axsendo Clinical Research - Houston- Site Number : 8400054Houston, United StatesNo longer taking part
- University of Florida - Jacksonville- Site Number : 8400126Jacksonville, United StatesTaking people
- Critical Care Pulmonary & Sleep Associates- Site Number : 8400081Lakewood, United StatesTaking people
- Excel Clinical Research - Las Vegas- Site Number : 8400070Las Vegas, United StatesTaking people
- Las VegasLas Vegas, United StatesNo longer taking part
- Lehigh AcresLehigh Acres, United StatesTaking people
- Long BeachLong Beach, United StatesTaking people
- Los AngelesLos Angeles, United StatesTaking people
- Alliance Clinical - West Hills- Site Number : 8400067Los Angeles, United StatesTaking people
- Pulmonary Specialists of the Palm Beaches- Site Number : 8400017Loxahatchee Groves, United StatesTaking people
- Suburban Research Associates - Media- Site Number : 8400143Media, United StatesTaking people
- MiamiMiami, United StatesTaking people
- MiamiMiami, United StatesTaking people
- Elite Clinical Research - Miami- Site Number : 8400167Miami, United StatesTaking people
- Phoenix Medical Research - Miami - 24th Street- Site Number : 8400027Miami, United StatesTaking people
- Professional Research Center- Site Number : 8400046Miami, United StatesTaking people
- Research Institute of South Florida- Site Number : 8400028Miami, United StatesTaking people
- Synergy Group US - Missouri City- Site Number : 8400119Missouri City, United StatesTaking people
- Synergy Group US - Missouri City- Site Number : 8400133Missouri City, United StatesTaking people
- Pulmonary Associates - Mobile- Site Number : 8400151Mobile, United StatesTaking people
- New BedfordNew Bedford, United StatesTaking people
- Mid Hudson Medical Research - New Windsor- Site Number : 8400004New Windsor, United StatesTaking people
- Rutgers Institute For Infectious & Inflammatory Diseases (I3d)- Site Number : 8400093Newark, United StatesTaking people
- Sneeze Wheeze & Itch Associates- Site Number : 8400020Normal, United StatesTaking people
- California Medical Research Associates - Northridge- Site Number : 8400089Northridge, United StatesTaking people
- OrlandoOrlando, United StatesTaking people
- Florida Institute for Clinical Research- Site Number : 8400001Orlando, United StatesTaking people
- Avanza Medical Research Center- Site Number : 8400015Pensacola, United StatesTaking people
- Peoria Pulmonary Associates Ltd- Site Number : 8400095Peoria, United StatesTaking people
- Hull and Hull Medical Specialists- Site Number : 8400002Plantation, United StatesTaking people
- The Oregon Clinic - Portland - Northwest 22nd Avenue- Site Number : 8400065Portland, United StatesTaking people
- San DiegoSan Diego, United StatesNo longer taking part
- Windom Allergy, Asthma and Sinus Specialists- Site Number : 8400041Sarasota, United StatesTaking people
- Care Access - Shreveport - Youree Drive- Site Number : 8400007Shreveport, United StatesTaking people
- Ochsner LSU Health Shreveport - Academic Medical Center- Site Number : 8400083Shreveport, United StatesTaking people
- Washington University- Site Number : 8400144St Louis, United StatesTaking people
- Stat Care Pulmonary and Sleep- Site Number : 8400138St. Petersburg, United StatesTaking people
- Piedmont Healthcare - Family Medicine- Site Number : 8400022Statesville, United StatesNo longer taking part
- Elligo Health Care, Hillcroft Medical Clinic Association- Site Number : 8400053Sugar Land, United StatesTaking people
- TampaTampa, United StatesTaking people
- TampaTampa, United StatesTaking people
- Asthma & Allergy Center - Toledo- Site Number : 8400110Toledo, United StatesTaking people
- Tucson Clinical Research Institute- Site Number : 8400006Tucson, United StatesTaking people
- TulsaTulsa, United StatesTaking people
- Howard University Hospital- Site Number : 8400080Washington D.C., United StatesTaking people
- Winston-SalemWinston-Salem, United StatesTaking people
- Medrasa Clinical Research - Wylie- Site Number : 8400124Wylie, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sanofi
- Trial code
- NCT07190222EU 2024-518213-25-00
- Record updated
- 23 October 2026
- Original description
This is a parallel, Phase 2b/Phase 3, 3-arm study to investigate the efficacy, safety, and tolerability of subcutaneous (SC) treatment with lunsekimig compared with placebo in adult participants (aged 40 to 80 years, inclusive) with inadequately controlled Chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype.Read full original descriptionShow less
A Phase 2b/Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study, to Investigate the Efficacy and Safety of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
This is a parallel, Phase 2b/Phase 3, 3-arm study to investigate the efficacy, safety, and tolerability of subcutaneous (SC) treatment with lunsekimig compared with placebo in adult participants (aged 40 to 80 years, inclusive) with inadequately controlled Chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype.
Participation to the study consists of 3 periods:
* Screening period of up to 4 weeks * Randomized intervention period of approximately 48 weeks * Follow-up period: Approximately 8 weeks The study duration will be up to 60 weeks.
Inclusion: Between 40 to 80 years of age; Physician diagnosed chronic obstructive pulmonary disease (COPD) ≥1 year; Post-bronchodilator forced expiratory volume in 1 second (post-BD FEV1) ≥ 20% and ≤ 70% of predicted value and FEV1/FVC (forced expiratory volume in 1 second /forced vital capacity) <0.70; Former or current smokers ≥10 pack-years; Chronic Airways Assessment Test (CAAT) ≥10; ≥2 moderate or ≥1 severe COPD exacerbations in the prior year; Triple (ICS+LABA+LAMA) COPD therapy ≥12 consecutive weeks; EOS (blood eosinophil count) ≥ 150 cells/μL; 18.0 ≤ Body Mass Index ≤ 40.0 kg/m2.
Exclusion: Long-term oxygen therapy >4.0 L/min or requirement of >2.0 L/min to maintain oxygen saturation >88% at rest; Concomitant therapies:; long-term macrolides or phosphodiesterase Type 3 (PDE-3) or PDE-4 inhibitors unless on stable therapy for > 6 months; any biologic therapy or systemic immunosuppressant within 4 months or 5 half-lives prior to Screening; The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial; Asthma, including pediatric asthma, or asthma-COPD overlap syndrome (ACOS); Significant pulmonary disease other than COPD; Unstable disorder that can impact participants safety or study outcomes; Active or incompletely treated tuberculosis; Current or past malignancies; Participants are excluded from the study if any of the following criteria apply:.